ADMA Biologics is trading 9.21% up in pre-market at $10.20 after BlackRock disclosed ownership of 38,355,684 shares, representing about 16.5% of the company.
- The stake is valued at approximately $321 million, and the disclosure was reported on August 27, 2026.
- It is the clearest catalyst for the August 31 pre-market rally; no newer company announcement was identified.
- Broader markets are modestly lower, making the company-specific institutional investment the dominant explanation.